Originally published by our sister publication Infectious Disease Special Edition
By Marie Rosenthal
The long-acting cabotegravir plus rilpivirine (CAB+RPV LA) antiretroviral therapy was as effective as daily bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF) in maintaining viral suppression among patients with HIV, but many people preferred the injection to daily pills, according to research presented at CROI 2023, in Seattle.
The phase 3b SOLAR (Switch Onto Long Acting Regimen) study